|
WO2021074689A1
|
|
Immunomodulatory il-2 agents in combination with immune checkpoint inhibitors
|
|
US2021052694A1
|
|
Compositions and methods for subcutaneous administration of cancer immunotherapy
|
|
US2020325157A1
|
|
Thiophene compounds for long-acting injectable compositions and related methods
|
|
US2020017529A1
|
|
Thienothiophene compounds for long-acting injectable compositions and related methods
|
|
WO2020012248A1
|
|
Novel naphthylenyl compounds for long-acting injectable compositions and related methods
|
|
CA3092335A1
|
|
Aripiprazole dosing strategy
|
|
CA3014788A1
|
|
Compositions of multiple aripiprazole prodrugs
|
|
AU2016204605A1
|
|
Prodrugs of nh-acidic compounds
|
|
AU2015268652A1
|
|
Ligands modified by circular permutation as agonists and antagonists
|
|
US2017136004A1
|
|
Opioid agonist antagonist combinations
|
|
CN111454207A
|
|
Crystallization method of aripiprazole derivatives in sustained-release preparation for treating schizophrenia
|
|
MX2017002029A
|
|
Aripiprazole prodrug compositions.
|
|
HUE043169T2
|
|
Aripiprazole prodrug compositions
|
|
US2016045495A1
|
|
Aripiprazole prodrug compositions
|
|
CN106132415A
|
|
There is the aripiprazole formulations of the injection speed of increase
|
|
CA2972179A1
|
|
Monomethylfumarate prodrug compositions
|
|
NZ723269A
|
|
Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
|
|
AU2014265021A1
|
|
Prodrugs of nh-acidic compounds
|
|
CA2870380A1
|
|
Abuse resistant pharmaceutical compositions
|
|
AU2014233560A1
|
|
Drug delivery composition
|
